Cybin announces additional adelia milestone achievement

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biotechnology company focused on progressing “psychedelics to therapeutics™”, is pleased to announce that adelia therapeutics inc. (“adelia”), a wholly-controlled subsidiary of cybin, has achieved the milestones identified as year 1 q4 (vi); year 2 q2 (ii); year 2 q2 (v) and year 2, q3 (iii) as contemplated by the terms of a contribution agreement dated december 4, 2020 (the “transaction agreement
CYBN Ratings Summary
CYBN Quant Ranking